TOP STORIES

• REGULATORY Data Error Delayed Japan Review of Subcutaneous Rybrevant; Approval Still Expected This Year
  October 30, 2025

• REGULATORY Public-Private WG’s Discussion Summary Focuses on Drug Pricing, Raises MFN Risk
  October 29, 2025

• BUSINESS NEC Crafts Data Platform to Advance Personalized Cancer Vaccine Program
  October 28, 2025

• BUSINESS Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
  October 28, 2025

• BUSINESS Novo to End Sales of Victoza in Japan, Fourth GLP-1 to Exit Market
  October 28, 2025

• BUSINESS First Oral Small-Molecule GLP-1 Nears Filing; Broad Use Expected in Diabetes
  October 27, 2025

• BUSINESS Chugai Acquires Renalys Pharma, Bags IgAN Drug
  October 27, 2025

• BUSINESS Celltrion Files Biosimilar without Japanese Clinical Data, More Firms Might Follow
  October 24, 2025

• BUSINESS Earnings Season Kicks Off, Off-Year Revision Impact in Spotlight
  October 24, 2025

• BUSINESS And Pharma Group Subsidiaries Team Up for First Joint Promotion
  October 23, 2025

• REGULATORY MHLW Sets Interim Nitrosamine Limit for Atomoxetine, 5 Generic Makers Launch Fresh Recalls
  October 23, 2025

• REGULATORY Public-Private WG to Compile Industry Proposals on Drug Pricing Reforms at Next Session
  October 23, 2025

• ORGANIZATION MFN Drug Pricing Already Affecting 4 Firms’ R&D Plans in Japan, EFPIA Chief Flags Fallout
  October 22, 2025

• REGULATORY LDP, Nippon Ishin to Form Coalition; OTC-Like Drug Copay Review Set for FY2025
  October 21, 2025

• BUSINESS Chiesi Japan to Expand Workforce Tenfold by 2030 on Back of New Drug Filings
  October 20, 2025

• REGULATORY MHLW Panel Launches Full Debate on Drug Coverage Reform; LLPs, Biologics, OTC-Like Meds in Focus
  October 17, 2025

• BUSINESS Viatris Snaps Up Japan’s Aculys Pharma, Gains 2 CNS Assets
  October 17, 2025

• BUSINESS Organon Bids Farewell to 1990s Blockbusters Lipovas and Renivace in Japan
  October 16, 2025

• REGULATORY Deeper CEA Price Cuts Mooted for “Cost Increase” Products: FY2026 Reform Debate
  October 16, 2025

• REGULATORY Chuikyo Urges Stricter Pricing Rules for Conditionally Approved Regenerative Medicines
  October 16, 2025

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »